Acclarent, a developer and marketer of medical devices, has closed a $26 million financing round.
Subscribe to our email newsletter
Acclarent intends to use the proceeds to continue commercialization of its Balloon Sinuplasty technology, as well as on-going investment in product development and clinical studies.
Johnson & Johnson Development joined existing prominent investors New Enterprise Associates, Delphi Ventures, Versant Ventures, and Meritech Capital Partners in this financing.
Bill Facteau, president and CEO of Acclarent, said: “The addition of Johnson & Johnson Development together with the support of our existing financial partners will enable Acclarent to continue executing on our strategy to build the preeminent ENT Company.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.